Schiewek et al. also reported that higher KIF18A expression in ovarian cancer tumors, compared to borderline tumors, is associated with late-stage presentation at diagnosis (FIGO IIIC-IV) and poor clinical outcome [7]. This evidence concerns the gene KIF18A and ovarian carcinoma.